JP Morgan Chase
TCRT icon

JP Morgan Chase’s Alaunos Therapeutics TCRT Stock Holding History

JP Morgan Chase’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-778
Closed -$383K – 5773
2020
Q2 		$383K Buy
778
+728
+1,456% +$325K ﹤0.01% 3965
2020
Q1 		$18K Sell
50
-655
-93% -$339K ﹤0.01% 4974
2019
Q4 		$499K Sell
705
-5,118
-88% -$3.52M ﹤0.01% 4240
2019
Q3 		$3.74M Buy
5,823
+1,814
+45% +$1.44M ﹤0.01% 2930
2019
Q2 		$3.45M Buy
4,009
+3,622
+936% +$2.49M ﹤0.01% 2938
2019
Q1 		$223K Buy
+387
New +$162K ﹤0.01% 4590

Other funds holding TCRT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
CIBC Private Wealth Group
CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

JP Morgan Chase's TCRT Position: Q3 2025 in Review

JP Morgan Chase sold out of Alaunos Therapeutics (TCRT) in Q3 2025, closing a stake of 3 shares — an estimated $15 sold.

JP Morgan Chase first reported a position in TCRT in Q2 2013 and held it in 36 quarters. The position peaked at $18.9M in Q1 2021. 26 funds tracked by Wall St. Rank hold TCRT as of Q3 2025.

  • JP Morgan Chase reported no remaining Alaunos Therapeutics position as of Q3 2025 after selling out during the quarter.
  • JP Morgan Chase sold 3 Alaunos Therapeutics shares in Q3 2025, an estimated $15.
  • JP Morgan Chase first reported a position in Alaunos Therapeutics in Q2 2013 and held it in 36 quarters.
  • JP Morgan Chase's Alaunos Therapeutics position peaked at $18.9M in Q1 2021.
  • 26 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q3 2025.

Based on JP Morgan Chase's 13F filing for Q3 2025, filed 7 Nov 2025.